Meanwhile, Eli Lilly's Zepbound injection has gained traction, prompting both firms to race toward more convenient ...

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...

Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 ...

according to the company. The level of weight loss was similar to that achieved over the same period with Novo Nordisk’s injection but slightly lower than that with Eli Lilly’s injection in ...

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to expect from LLY's Q1 results.

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best income stocks. Amid concerns over trade restrictions and a weakening economy ...

Eli Lilly GLP-1 pill orforglipron could revolutionize the weight loss world by the end of 2025 after promising Phase 3 trial results.

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.

Eli Lilly and Purdue University expand their partnership with a $250 million investment to advance pharmaceutical innovation ...

Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of diabetes patients, and the company said it expects to seek regulatory approvals ...

Lilly turned in strong first-quarter ... hurt the shares. The company's new oral GLP-1 drug, which avoids the use of injections, has huge potential. The company's GLP-1 drugs continue to drive ...

“Injections cannot be the solution ... this article misstated the amount of orforglipron pills Eli Lilly has produced so far. The company said that it manufactured about $500 million worth ...